Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Halts Development of TERN-601 for Obesity
Summary
On October 21, 2025, Terns Pharmaceuticals, Inc. announced the topline results from its Phase 2 trial of TERN-601, an oral GLP-1 receptor agonist for obesity treatment. The trial did not meet the safety, tolerability, and efficacy threshold, with 12% treatment discontinuation due to adverse events, including gastrointestinal issues and grade 3 liver enzyme elevations in three participants. Consequently, the company has decided not to advance TERN-601 or invest further in metabolic disease treatments, focusing instead on its TERN-701 program for chronic myeloid leukemia.
Profitelligence Alerts
Get alerts for TERN
Be first to know when Terns Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic candidates targeting liver disease and oncology. Its primary function is to advance its pipeline of clinical and preclinical drug candidates that address significant unmet medical needs. One of the company's main focuses is on non-alcoholic steatohepatitis (NASH), a progressive liver disease. Through innovative approaches, Terns Pharmaceuticals explores various mechanisms to treat NASH, including small molecules designed to reduce liver inflammation and fibrosis. Beyond liver disease, the company is expanding its platform to include oncology, diversifying its impact in the healthcare industry. As a key player in the biopharmaceutical sector, Terns Pharmaceuticals Inc. contributes to the growing landscape of targeted therapies. With a dedicated emphasis on research and development, the company plays an essential role in pushing the boundaries of treatment options, potentially transforming the management of chronic liver diseases and cancer.
Official SEC Documents
Advertisement